🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. Istaroxime

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    2 trials

  2. Istaroxime, LActose

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    1 trial

  3. JDB0131

    China SXT Pharmaceuticals

    Drug-resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib

    Fondazione Telethon ETS

    Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  7. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  8. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  9. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  10. Lapaquistat acetate and fenofibrate

    Takeda Pharmaceuticals International AG

    Hyperlipidemias

    phase 2 small molecule completed

    1 trial

  11. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  12. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  13. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  14. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Ophthalmics Europe

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  15. MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

    Orion

    Metastatic castration-resistant prostate cancer.

    phase 2 small molecule active

    1 trial

  16. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  17. Metformin Zentiva 500 mg Filmtabletten

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Multidrug rezistant pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  18. Mifepristone 1200 mg daily

    CORCEPT THERAPEUTICS INC

    Treatment-resistant PTSD

    phase 2 small molecule active

    1 trial

  19. NRX 194204

    IO Biotech

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  20. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  21. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  22. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  23. Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  24. PCN-101

    PRECISION BIOSCIENCES INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources